Current advances of tubulin inhibitors in nanoparticle drug delivery and vascular disruption/angiogenesis

Molecules

Volumn 21, Issue 11, 2016, Pages

  Banerjee, Souvik ^a   Hwang, Dong Jin ^a   Li, Wei ^a   Miller, Duane D ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiogenesis; Antimitotic; Multidrug resistance; Nanoparticle formulations; Tubulin dynamics; Tubulin inhibitors; Vascular disrupting agent; tubulin isotypes and drug resistance

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE; PROTEIN BINDING; TUBULIN; TUBULIN MODULATOR;

ANGIOGENESIS; ANIMAL; BINDING SITE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; TUBULIN; TUBULIN MODULATORS;

EID: 84994059918     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21111468     Document Type: Review

References (120)

1. 3H to cellular protein. J. Cell Biol. 1967, 34, 525-533.
2. Bunker, J. M.; Wilson, L.; Jordan, M. A.; Feinstein, S. C. Modulation of microtubule dynamics by tau in living cells: Implications for development and neurodegeneration. Mol. Biol. Cell 2004, 15, 2720-2728.
3. Risinger, A. L.; Dybdal-Hargreaves, N. F.; Mooberry, S. L. Breast cancer cell lines exhibit differential sensitivities to microtubule-targeting drugs independent of doubling time. Anticancer Res. 2015, 35, 5845-5850.
4. Perez-Elias, M. J.; Morellon, M. L.; Ortega, E.; Hernandez-Quero, J.; Rodriguez-Torres, M.; Clotet, B.; Felizarta, F.; Gutierrez, F.; Pineda, J. A.; Nichols, G.; et al. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob. Agents Chemother. 2009, 53, 5185-5196.
5. Gan, P. P.; McCarroll, J. A.; Po'uha, S. T.; Kamath, K.; Jordan, M. A.; Kavallaris, M. Microtubule dynamics, mitotic arrest, and apoptosis: Drug-induced differential effects of βIII-tubulin. Mol. Cancer Ther. 2010, 9, 1339-1348.
6. Brouhard, G. J.; Rice, L. M. The contribution of αβ-tubulin curvature to microtubule dynamics. J. Cell Biol. 2014, 207, 323-334.
7. Zhao, Y.; Mu, X.; Du, G. Microtubule-stabilizing agents: New drug discovery and cancer therapy. Pharmacol. Ther. 2016, 162, 134-143.
8. Fanale, D.; Bronte, G.; Passiglia, F.; Calo, V.; Castiglia, M.; Di Piazza, F.; Barraco, N.; Cangemi, A.; Catarella, M. T.; Insalaco, L.; et al. Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? Anal. Cell. Pathol. 2015, 2015, 690916.
9. Morris, P. G.; Fornier, M. N. Microtubule active agents: Beyond the taxane frontier. Clin. Cancer Res. 2008, 14, 7167-7172.
10. Hwang, D. J.; Wang, J.; Li, W.; Miller, D. D. Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents. ACS Med. Chem. Lett. 2015, 6, 993-997.
11. Prota, A. E.; Bargsten, K.; Northcote, P. T.; Marsh, M.; Altmann, K. H.; Miller, J. H.; Diaz, J. F.; Steinmetz, M. O. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew. Chem. Int. Ed. Engl. 2014, 53, 1621-1625.
12. Perez, E. A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther. 2009, 8, 2086-2095.
13. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.
14. Spear, M. A.; LoRusso, P.; Mita, A.; Mita, M. Vascular disrupting agents (VDA) in oncology: Advancing towards new therapeutic paradigms in the clinic. Curr. Drug Targets 2011, 12, 2009-2015.
15. Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat. Rev. 2011, 37, 63-74.
16. Prokopiou, E. M.; Ryder, S. A.; Walsh, J. J. Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 2013, 16, 503-524.
17. Lobert, S. G.; Mary, E. Regulation of tubulin expression by micro-RNA: Implications drug resistance. Methods Cell Biol. 2013, 115, 63-74.
18. Lu, Y.; Chen, J.; Xiao, M.; Li, W.; Miller, D. D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res. 2012, 29, 2943-2971.
19. Ji, Y. T.; Liu, Y. N.; Liu, Z. P. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments. Curr. Med. Chem. 2015, 22, 1348-1360.
20. Wang, X.-F.; Guan, F.; Ohkoshi, E.; Guo, W.; Wang, L.; Zhu, D.-Q.; Wang, S.-B.; Wang, L.-T.; Hamel, E.; Yang, D.; et al. Optimization of 4-(N-cycloamino) phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site. J. Med. Chem. 2014, 57, 1390-1402.
21. Solum, E. J.; Cheng, J.-J.; Sørvik, I. B.; Paulsen, R. E.; Vik, A.; Hansen, T. V. Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: Inhibitors of tubulin and angiogenesis. Eur. J. Med. Chem. 2014, 85, 391-398.
22. O'Boyle, N. M.; Pollock, J. K.; Carr, M.; Knox, A. J. S.; Nathwani, S. M.; Wang, S.; Caboni, L.; Zisterer, D. M.; Meegan, M. J. B-lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand. J. Med. Chem. 2014, 57, 9370-9382.
23. Gangjee, A.; Pavana, R. K.; Ihnat, M. A.; Thorpe, J. E.; Disch, B. C.; Bastian, A.; Bailey-Downs, L. C.; Hamel, E.; Bai, R. Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential. ACS Med. Chem. Lett. 2014, 5, 480-484.
24. 4H-chromenes as anticancer agents. Bioorg. Med. Chem. Lett. 2012, 22, 4458-4461.
25. Chen, W.; Seefeldt, T.; Young, A.; Zhang, X.; Zhao, Y.; Ruffolo, J.; Kaushik, R. S.; Guan, X. Microtubule S-glutathionylation as a potential approach for antimitotic agents. BMC Cancer 2012, 12.
26. Mundra, V.; Peng, Y.; Kumar, V.; Li, W.; Miller, D. D.; Mahato, R. I. Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma. Drug Deliv. Transl. Res. 2015, 5, 199-208.
27. Athawale, R. B.; Jain, D. S.; Singh, K. K.; Gude, R. P. Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed. Pharmacother. 2014, 68, 231-240.
28. Mundra, V.; Lu, Y.; Danquah, M.; Li, W.; Miller, D. D.; Mahato, R. I. Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent. Pharm. Res. 2012, 29, 3064-3074.
29. Schluep, T.; Gunawan, P.; Ma, L.; Jensen, G. S.; Duringer, J.; Hinton, S.; Richter, W.; Hwang, J. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin. Cancer Res. 2009, 15, 181-189.
30. Reddy, J. A.; Dorton, R.; Westrick, E.; Dawson, A.; Smith, T.; Xu, L.-C.; Vetzel, M.; Kleindl, P.; Vlahov, I. R.; Leamon, C. P. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007, 67, 4434-4442.
31. Carter, P. J.; Senter, P. D. Antibody-drug conjugates for cancer therapy. Cancer J. 2008, 14, 154-169.
32. Thomas, A.; Teicher, B. A.; Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016, 17, e254-e262.
33. Polakis, P. Antibody drug conjugates for cancer therapy. Pharmacol. Rev. 2016, 68, 3-19.
34. Vicent, M. J. Polymer-drug conjugates as modulators of cellular apoptosis. AAPS J. 2007, 9, E200-E207.
35. Kaur, G.; Hollingshead, M.; Holbeck, S.; Schauer-Vukašinović, V.; Camalier, R. F.; Dömling, A.; Agarwal, S. Biological evaluation of tubulysin A: A potential anticancer and antiangiogenic natural product. Biochem. J. 2006, 396, 235-242.
36. Steinmetz, H.; Glaser, N.; Herdtweck, E.; Sasse, F.; Reichenbach, H.; Höfle, G. Isolation, crystal and solution structure determination, and biosynthesis of tubulysins-Powerful inhibitors of tubulin polymerization from myxobacteria. Angew. Chem. Int. Ed. Engl. 2004, 43, 4888-4892.
37. Khalil, M. W.; Sasse, F.; Lünsdorf, H.; Elnakady, Y. A.; Reichenbach, H. Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. ChemBioChem 2006, 7, 678-683.
38. Murray, B. C.; Peterson, M. T.; Fecik, R. A. Chemistry and biology of tubulysins: Antimitotic tetrapeptides with activity against drug resistant cancers. Nat. Prod. Rep. 2015, 32, 654-662.
39. Nicolaou, K. C.; Yin, J.; Mandal, D.; Erande, R. D.; Klahn, P.; Jin, M.; Aujay, M.; Sandoval, J.; Gavrilyuk, J.; Vourloumis, D. Total synthesis and biological evaluation of natural and designed tubulysins. J. Am. Chem. Soc. 2016, 138, 1698-1708.
40. Colombo, R.; Wang, Z.; Han, J.; Balachandran, R.; Daghestani, H. N.; Camarco, D. P.; Vogt, A.; Day, B. W.; Mendel, D.; Wipf, P. Total synthesis and biological evaluation of tubulysin analogues. J. Org. Chem. 2016.
41. Xu, X.; Gregory, K. F.; Yao, L. Recent advances in the synthesis of tubulysins. Mini Rev. Med. Chem. 2013, 13, 1572-1578.
42. Sendur, M. A.; Aksoy, S.; Ozdemir, Y.; Zengin, N.; Altundag, K. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? J. BUON 2013, 18, 801.
43. Bighin, C.; Pronzato, P.; Del Mastro, L. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Future Oncol. 2013, 9, 955-957.
44. Poon, K. A.; Flagella, K.; Beyer, J.; Tibbitts, J.; Kaur, S.; Saad, O.; Yi, J. H.; Girish, S.; Dybdal, N.; Reynolds, T. Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol. Appl. Pharmacol. 2013, 273, 298-313.
45. Tang, X.; Liang, Y.; Zhu, Y.; Cai, S.; Sun, L.; Chen, T. Enhanced anticancer activity of DM1-loaded star-shaped folate-core PLA-TPGS nanoparticles. Nanoscale Res. Lett. 2014, 9.
46. Haddley, K. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. Drugs Today 2013, 49, 701-715.
47. Thery, J.-C.; Spano, J.-P.; Azria, D.; Raymond, E.; Penault Llorca, F. Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur. J. Cancer 2014, 50, 892-901.
48. Ye, P.; Zhang, W.; Yang, T.; Lu, Y.; Lu, M.; Gai, Y.; Ma, X.; Xiang, G. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int. J. Nanomed. 2014, 9, 2167-2178.
49. Hu, Y.; Ma, B.; Zhang, Y.; Wang, M. Small molecule-folic acid modification on nanopatterned PDMS and investigation on its surface property. Biomed. Microdevices 2014, 16, 487-497.
50. Leamon, C. P.; Vlahov, I. R.; Reddy, J. A.; Vetzel, M.; Santhapuram, H. K.; You, F.; Bloomfield, A.; Dorton, R.; Nelson, M.; Kleindl, P.; et al. Folate-vinca alkaloid conjugates for cancer therapy: A structure-activity relationship. Bioconjug. Chem. 2014, 25, 560-568.
51. Shi, J.; Wang, L.; Gao, J.; Liu, Y.; Zhang, J.; Ma, R.; Liu, R.; Zhang, Z. A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials 2014, 35, 5771-5784.
52. Zheng, M.; Zhao, P.; Luo, Z.; Gong, P.; Zheng, C.; Zhang, P.; Yue, C.; Gao, D.; Ma, Y.; Cai, L. Robust ICG theranostic nanoparticles for folate targeted cancer imaging and highly effective photothermal therapy. ACS Appl. Mater. Interfaces 2014, 6, 6709-6716.
53. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63, 131-135.
54. Jana, B.; Mohapatra, S.; Mondal, P.; Barman, S.; Pradhan, K.; Saha, A.; Ghosh, S. A-cyclodextrin interacts close to vinblastine site of tubulin and delivers curcumin preferentially to the tubulin surface of cancer cell. ACS Appl. Mater. Interfaces 2016, 8, 13793-13803.
55. Pérez-Pérez, M.-J.; Priego, E.-M.; Bueno, O.; Martins, M. S.; Canela, M.-D.; Liekens, S. Blocking blood flow to solid tumors by destabilizing tubulin: An approach to targeting tumor growth. J. Med. Chem. 2016, 59, 8685-8711.
56. Tangutoori, S.; Ohta, A.; Gatley, S.; Campbell, B. R. Repurposing an erstwhile cancer drug: A quantitative and therapeutic evaluation of alternative nanosystems for the delivery of colchicine to solid tumors. J. Cancer Sci. Ther. 2014, 6, 236-246.
57. Tortorici, M. A.; Skledar, S.; Barnes, B.; Wasko, M. C. Promoting the safe use of intravenous colchicine. Am. J. Health Syst. Pharm. 2004, 61, 2496-2501.
58. Deveaux, M.; Hubert, N.; Demarly, C. Colchicine poisoning: Case report of two suicides. Forensic. Sci. Int. 2004, 143, 219-222.
59. Fernandez, S.; Castro, P.; Nogue, S.; Nicolas, J. M. Refractory shock and severe leukopenia with multisystemic organ failure due to colchicine intentional overdose. Med. Clin. 2014, 143, 140.
60. Suh, J.; Choy, K.-L.; Lai, S. K.; Suk, J. S.; Tang, B. C.; Prabhu, S.; Hanes, J. Pegylation of nanoparticles improves their cytoplasmic transport. Int. J. Nanomed. 2007, 2, 735-741.
61. Lu, Y.; Li, C.-M.; Wang, Z.; Ross, C. R.; Chen, J.; Dalton, J. T.; Li, W.; Miller, D. D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: Synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 2009, 52, 1701-1711.
62. Lu, Y.; Li, C.-M.; Wang, Z.; Chen, J.; Mohler, M. L.; Li, W.; Dalton, J. T.; Miller, D. D. Design, synthesis, and sar studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J. Med. Chem. 2011, 54, 4678-4693.
63. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436, 568-572.
64. Li, X.; Wu, M.; Pan, L.; Shi, J. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. Int. J. Nanomed. 2016, 11, 93-105.
65. Sumer Bolu, B.; Manavoglu Gecici, E.; Sanyal, R. Combretastatin A-4 conjugated antiangiogenic micellar drug delivery systems using dendron-polymer conjugates. Mol. Pharm. 2016, 13, 1482-1490.
66. ®) by the pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 2015, 62, 1214-1221.
67. Desai, N.; Trieu, V.; Damascelli, B.; Soon-Shiong, P. Sparc expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2, 59-64.
68. De Leon, M. C. B.; Bolla, S.; Greene, B.; Hutchinson, L.; Del Priore, G. Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol. Oncol. Case Rep. 2013, 5, 70-71.
69. ® ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4, 99-105.
70. Kretschmar, C. S.; Kletzel, M.; Murray, K.; Thorner, P.; Joshi, V.; Marcus, R.; Smith, E. I.; London, W. B.; Castleberry, R. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: A pediatric oncology group study. J. Clin. Oncol. 2004, 22, 4119-4126.
71. Doz, F.; Gentet, J. C.; Pein, F.; Frappaz, D.; Chastagner, P.; Moretti, S.; Vassal, G.; Arditti, J.; Tellingen, O. V.; Iliadis, A.; et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: A SFOP study. Br. J. Cancer 2001, 84, 604-610.
72. Kolb, E. A.; Gorlick, R.; Reynolds, C. P.; Kang, M. H.; Carol, H.; Lock, R.; Keir, S. T.; Maris, J. M.; Billups, C. A.; DesJardins, C.; et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr. Blood Cancer 2013, 60, 1325-1332.
73. Wong, H.; Choo, E. F.; Alicke, B.; Ding, X.; La, H.; McNamara, E.; Theil, F.-P.; Tibbitts, J.; Friedman, L. S.; Hop, C. E. C. A.; et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin. Cancer Res. 2012, 18, 3846-3855.
74. Desai, N. P.; Trieu, V.; Hwang, L. Y.; Wu, R.; Soon-Shiong, P.; Gradishar, W. J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Drugs 2008, 19, 899-909.
75. Mielke, S.; Sparreboom, A.; Steinberg, S. M.; Gelderblom, H.; Unger, C.; Behringer, D.; Mross, K. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 2005, 11, 4843-4850.
76. Mielke, S.; Sparreboom, A.; Mross, K. Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur. J. Cancer 2006, 42, 24-30.
77. Knemeyer, I.; Wientjes, G. M.; Au, L. S. J. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother. Pharmacol. 1999, 44, 241-248.
78. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794-7803.
79. Kundranda, M. N.; Niu, J. Albumin-bound paclitaxel in solid tumors: Clinical development and future directions. Drug Des. Dev. Ther. 2015, 9, 3767-3777.
80. Gupta, N.; Hatoum, H.; Dy, G. K. First line treatment of advanced non-small-cell lung cancer-Specific focus on albumin bound paclitaxel. Int. J. Nanomed. 2014, 9, 209-221.
81. Von Hoff, D. D.; Ervin, T.; Arena, F. P.; Chiorean, E. G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S. A.; Ma, W. W.; Saleh, M. N.; et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369, 1691-1703.
82. Bansal, A.; Kapoor, D. N.; Kapil, R.; Chhabra, N.; Dhawan, S. Design and development of paclitaxel-loaded bovine serum albumin nanoparticles for brain targeting. Acta Pharm. 2011, 61, 141-156.
83. Wang, B.; Lv, L.; Wang, Z.; Jiang, Y.; Lv, W.; Liu, X.; Wang, Z.; Zhao, Y.; Xin, H.; Xu, Q. Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel. Sci. Rep. 2015, 5.
84. Yi, X.; Lian, X.; Dong, J.; Wan, Z.; Xia, C.; Song, X.; Fu, Y.; Gong, T.; Zhang, Z. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers. Mol. Pharm. 2015, 12, 4085-4098.
85. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
86. Kanthou, C.; Tozer, G. M. Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton. Drug Discov. Today. Ther. Strateg. 2007, 4, 237-243.
87. Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A. L. M.; Horsman, M. R.; Marmé, D.; LoRusso, P. M. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 2005, 11, 416-420.
88. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
89. El-Kenawi, A. E.; El-Remessy, A. B. Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales. Br. J. Pharmacol. 2013, 170, 712-729.
90. Vasudev, N. S.; Reynolds, A. R. Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis 2014, 17, 471-494.
91. Romagnoli, R.; Baraldi, P. G.; Salvador, M. K.; Prencipe, F.; Lopez-Cara, C.; Schiaffino Ortega, S.; Brancale, A.; Hamel, E.; Castagliuolo, I.; Mitola, S.; et al. Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin. J. Med. Chem. 2015, 58, 3209-3222.
92. Porcù, E.; Viola, G.; Bortolozzi, R.; Persano, L.; Mitola, S.; Ronca, R.; Presta, M.; Romagnoli, R.; Baraldi, P. G.; Basso, G. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis 2013, 16, 647-662.
93. Ganguly, A.; Cabral, F.; Yang, H.; Patel, K. D. Peloruside a is a microtubule-stabilizing agent with exceptional anti-migratory properties in human endothelial cells. Oncoscience 2015, 2, 585-595.
94. Broggini-Tenzer, A.; Sharma, A.; Nytko, K. J.; Bender, S.; Vuong, V.; Orlowski, K.; Hug, D.; O'Reilly, T.; Pruschy, M. Combined treatment strategies for microtubule stabilizing agent-resistant tumors. J. Natl. Cancer Inst. 2015, 107.
95. Chan, A.; Singh, A. J.; Northcote, P. T.; Miller, J. H. Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A. Investig. New Drugs 2015, 33, 564-574.
96. Bocci, G.; Di Paolo, A.; Danesi, R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 2013, 16, 481-492.
97. Lu, H.; Murtagh, J.; Schwartz, E. L. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol. Pharmacol. 2006, 69, 1207-1215.
98. Zhu, S.; Kisiel, W.; Lu, Y. J.; Petersen, L. C.; Ndungu, J. M.; Moore, T. W.; Parker, E. T.; Sun, A.; Liotta, D. C.; El-Rayes, B. F.; et al. Tumor angiogenesis therapy using targeted delivery of paclitaxel to the vasculature of breast cancer metastases. J. Drug Deliv. 2014, 2014.
99. Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol. Pharmacol. 1988, 34, 200-208.
100. Massarotti, A.; Coluccia, A.; Silvestri, R.; Sorba, G.; Brancale, A. The tubulin colchicine domain: A molecular modeling perspective. ChemMedChem 2012, 7, 33-42.
101. Srivastava, V.; Negi, A. S.; Kumar, J. K.; Gupta, M. M.; Khanuja, S. P. S. Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bioorg. Med. Chem. 2005, 13, 5892-5908.
102. Horner, S. A.; Gould, S.; Noakes, J. P.; Rattray, N. J.; Allen, S. L.; Zotova, E.; Arezzo, J. C. Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. Dosing in the rat. Mol. Cancer Ther. 2004, 3, 783-791.
103. Pilat, M. J.; LoRusso, P. M. Vascular disrupting agents. J. Cell. Biochem. 2006, 99, 1021-1039.
104. Lee, J.; Bae, S.; Lee, S.-H.; Choi, H.; Kim, Y. H.; Kim, S. J.; Park, G. T.; Moon, S. K.; Kim, D.-H.; Lee, S.; et al. Discovery of a potent tubulin polymerization inhibitor: Synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg. Med. Chem. Lett. 2010, 20, 6327-6330.
105. Lee, J.; Kim, S. J.; Choi, H.; Kim, Y. H.; Lim, I. T.; Yang, H.-M.; Lee, C. S.; Kang, H. R.; Ahn, S. K.; Moon, S. K.; et al. Identification of CKD-516: A potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J. Med. Chem. 2010, 53, 6337-6354.
106. Kim, K. W.; Lee, J. M.; Jeon, Y. S.; Lee, I. J.; Choi, Y.; Park, J.; Kiefer, B.; Kim, C.; Han, J. K.; Choi, B. I. Vascular disrupting effect of CKD-516: Preclinical study using DCE-MRI. Investig. New Drugs 2013, 31, 1097-1106.
107. Oh, D.-Y.; Kim, T.-M.; Han, S.-W.; Shin, D.-Y.; Lee, Y. G.; Lee, K.-W.; Kim, J. H.; Kim, T.-Y.; Jang, I.-J.; Lee, J.-S.; et al. Phase i study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors. Cancer Res. Treat. 2016, 48, 28-36.
108. Kremmidiotis, G.; Leske, A. F.; Lavranos, T. C.; Beaumont, D.; Gasic, J.; Hall, A.; O'Callaghan, M.; Matthews, C. A.; Flynn, B. BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol. Cancer Ther. 2010, 9, 1562-1573.
109. Rischin, D.; Bibby, D. C.; Chong, G.; Kremmidiotis, G.; Leske, A. F.; Matthews, C. A.; Wong, S. S.; Rosen, M. A.; Desai, J. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: A phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin. Cancer Res. 2011, 17, 5152-5160.
110. Yakushiji, F.; Tanaka, H.; Muguruma, K.; Iwahashi, T.; Yamazaki, Y.; Hayashi, Y. Water-soluble prodrug of antimicrotubule agent plinabulin: Effective strategy with click chemistry. Chem. Eur. J. 2011, 17, 12587-12590.
111. Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G. K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M. A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Investig. New Drugs 2012, 30, 1065-1073.
112. Burns, C. J.; Harte, M. F.; Bu, X.; Fantino, E.; Joffe, M.; Sikanyika, H.; Su, S.; Tranberg, C. E.; Wilson, N.; Charman, S. A.; et al. Discovery of CYT997: A structurally novel orally active microtubule targeting agent. Bioorg. Med. Chem. Lett. 2009, 19, 4639-4642.
113. Burns, C. J.; Fantino, E.; Powell, A. K.; Shnyder, S. D.; Cooper, P. A.; Nelson, S.; Christophi, C.; Malcontenti-Wilson, C.; Dubljevic, V.; Harte, M. F.; et al. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo. J. Pharmacol. Exp. Ther. 2011, 339, 799-806.
114. Monaghan, K.; Khong, T.; Smith, G.; Spencer, A. CYT997 causes apoptosis in human multiple myeloma. Investig. New Drugs 2011, 29, 232-238.
115. Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.; et al. MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007, 67, 5865-5871.
116. Grossmann, K. F.; Colman, H.; Akerley, W. A.; Glantz, M.; Matsuoko, Y.; Beelen, A. P.; Yu, M.; De Groot, J. F.; Aiken, R. D.; Olsen, J. J.; et al. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J. Neurooncol. 2012, 110, 257-264.
117. Tsimberidou, A.-M.; Akerley, W.; Schabel, M. C.; Hong, D. S.; Uehara, C.; Chhabra, A.; Warren, T.; Mather, G. G.; Evans, B. A.; Woodland, D. P.; et al. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol. Cancer Ther. 2010, 9, 3410-3419.
118. Mahal, K.; Resch, M.; Ficner, R.; Schobert, R.; Biersack, B.; Mueller, T. Effects of the tumor-vasculaturedisrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem 2014, 9, 847-854.
119. Patil, S. A.; Patil, R.; Pfeffer, L. M.; Miller, D. D. Chromenes: Potential new chemotherapeutic agents for cancer. Future Med. Chem. 2013, 5, 1647-1660.
120. Banerjee, S.; Wang, J.; Pfeffer, S.; Ma, D.; Pfeffer, L.; Patil, S.; Li, W.; Miller, D. Design, synthesis and biological evaluation of novel 5H-chromenopyridines as potential anti-cancer agents. Molecules 2015, 20, 17152-17165.